Healthcare provider profile · identity verified

Jack C Wu, M.D.

Internal Medicine · LONG BEACH, CA · NPI 1326089079

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	352	98
Atorvastatin Calcium	Atorvastatin Calcium	300	78
Losartan Potassium	Losartan Potassium	292	73
Omeprazole	Omeprazole	196	58
Metformin Hcl	Metformin Hcl	194	54
Triamcinolone Acetonide	Triamcinolone Acetonide	166	65
Albuterol Sulfate Hfa	Albuterol Sulfate	158	39
Diclofenac Sodium	Diclofenac Sodium	154	43
Rosuvastatin Calcium	Rosuvastatin Calcium	149	46
Levothyroxine Sodium	Levothyroxine Sodium	146	37
Pantoprazole Sodium	Pantoprazole Sodium	145	38
Gabapentin	Gabapentin	139	38
Simvastatin	Simvastatin	128	34
Metoprolol Succinate	Metoprolol Succinate	115	35
Tramadol Hcl	Tramadol Hcl	112	22
Fluticasone Propionate	Fluticasone Propionate	111	42
Benazepril Hcl	Benazepril Hcl	107	30
Allopurinol	Allopurinol	106	30
Pravastatin Sodium	Pravastatin Sodium	96	22
Furosemide	Furosemide	89	32
Meloxicam	Meloxicam	83	22
Carvedilol	Carvedilol	80	19
Azelastine Hcl	Azelastine Hcl	76	24
Meclizine Hcl	Meclizine Hcl	76	27
Alendronate Sodium	Alendronate Sodium	71	19
Metoprolol Tartrate	Metoprolol Tartrate	67	18
Eliquis	Apixaban	61	suppressed
Clopidogrel	Clopidogrel Bisulfate	56	16
Azithromycin	Azithromycin	55	47
Januvia	Sitagliptin Phosphate	55	14
Vascepa	Icosapent Ethyl	54	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	53	18
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	52	17
Pregabalin	Pregabalin	51	15
Tradjenta	Linagliptin	51	suppressed
Lisinopril	Lisinopril	50	12
Tamsulosin Hcl	Tamsulosin Hcl	49	17
Hydralazine Hcl	Hydralazine Hcl	47	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	45	13
Baclofen	Baclofen	44	16
Potassium Chloride	Potassium Chloride	44	11
Montelukast Sodium	Montelukast Sodium	42	12
Olmesartan Medoxomil	Olmesartan Medoxomil	42	13
Celecoxib	Celecoxib	41	18
Famotidine	Famotidine	40	13
Jardiance	Empagliflozin	39	suppressed
Lorazepam	Lorazepam	38	11
Nifedipine Er	Nifedipine	38	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Glipizide	Glipizide	36	11
Hydrochlorothiazide	Hydrochlorothiazide	35	12
Clonidine Hcl	Clonidine Hcl	34	14
Ibuprofen	Ibuprofen	34	15
Propranolol Hcl	Propranolol Hcl	34	suppressed
Memantine Hcl	Memantine Hcl	33	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	32	suppressed
Atenolol	Atenolol	30	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Colchicine	Colchicine	29	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Acarbose	Acarbose	28	suppressed
Lidocaine	Lidocaine	28	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Fluocinonide	Fluocinonide	27	suppressed
Nateglinide	Nateglinide	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	suppressed
Ketoconazole	Ketoconazole	26	17
Loperamide	Loperamide Hcl	26	17
Clonidine	Clonidine	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Levetiracetam	Levetiracetam	25	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Prednisone	Prednisone	24	13
Trazodone Hcl	Trazodone Hcl	23	suppressed
Zenpep	Lipase/Protease/Amylase	23	suppressed
Amiodarone Hcl	Amiodarone Hcl	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Linzess	Linaclotide	21	suppressed
Ozempic	Semaglutide	20	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	19	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	19	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Valsartan	Valsartan	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	17
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Icosapent Ethyl	Icosapent Ethyl	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Ramipril	Ramipril	16	suppressed
Acetylcysteine	Acetylcysteine	15	suppressed
Aranesp	Darbepoetin Alfa In Polysorbat	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Minoxidil	Minoxidil	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Dulera	Mometasone/Formoterol	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Epinephrine	Epinephrine	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Lyrica	Pregabalin	12	suppressed
Prolia	Denosumab	12	suppressed
Ssd	Silver Sulfadiazine	12	suppressed
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	12	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Lactulose	Lactulose	11	suppressed
Temazepam	Temazepam	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error